Akeso: We’re The Leaders In Bispecific Cancer Immunotherapies

 
• By Andrew McConaghie
  
The Shenzhen middle channel bridge in the Pearl river delta connects the cities of Shenzen and Zhongshan, where Akeso is headquartered. (Shutterstock)

More from Clinical Trials

More from Therapy Areas